190 related articles for article (PubMed ID: 23370141)
1. Antiemetic effectiveness and safety of aprepitant in patients with hematologic malignancy receiving multiday chemotherapy.
Uchida M; Ikesue H; Kato K; Ichinose K; Hiraiwa H; Sakurai A; Takenaka K; Iwasaki H; Miyamoto T; Teshima T; Egashira N; Akashi K; Oishi R
Am J Health Syst Pharm; 2013 Feb; 70(4):343-9. PubMed ID: 23370141
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness and safety of antiemetic aprepitant in Japanese patients receiving high-dose chemotherapy prior to autologous hematopoietic stem cell transplantation.
Uchida M; Ikesue H; Miyamoto T; Kato K; Suetsugu K; Ichinose K; Hiraiwa H; Sakurai A; Takenaka K; Muta T; Iwasaki H; Teshima T; Shiratsuchi M; Egashira N; Akashi K; Oishi R
Biol Pharm Bull; 2013; 36(5):819-24. PubMed ID: 23649338
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of aprepitant in allogeneic hematopoietic stem cell transplantation.
Uchida M; Kato K; Ikesue H; Ichinose K; Hiraiwa H; Sakurai A; Muta T; Takenaka K; Iwasaki H; Miyamoto T; Teshima T; Shiratsuchi M; Suetsugu K; Nagata K; Egashira N; Akashi K; Oishi R
Pharmacotherapy; 2013 Sep; 33(9):893-901. PubMed ID: 23712662
[TBL] [Abstract][Full Text] [Related]
4. Aprepitant plus granisetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients with gastric cancer treated with S-1 plus cisplatin.
Oyama K; Fushida S; Kaji M; Takeda T; Kinami S; Hirono Y; Yoshimoto K; Yabushita K; Hirosawa H; Takai Y; Nakano T; Kimura H; Yasui T; Tsuneda A; Tsukada T; Kinoshita J; Fujimura T; Ohta T
J Gastroenterol; 2013 Nov; 48(11):1234-41. PubMed ID: 23338487
[TBL] [Abstract][Full Text] [Related]
5. Aprepitant for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving moderately emetogenic chemotherapy.
Inoue T; Kimura M; Uchida J; Nishino K; Kumagai T; Taniguchi J; Imamura F
Int J Clin Oncol; 2017 Jun; 22(3):600-604. PubMed ID: 28144884
[TBL] [Abstract][Full Text] [Related]
6. Phase II open label pilot trial of aprepitant and palonosetron for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately emetogenic FOLFOX chemotherapy for the treatment of colorectal cancer.
Bubalo JS; Herrington JD; Takemoto M; Willman P; Edwards MS; Williams C; Fisher A; Palumbo A; Chen E; Blanke C; Lopez CD
Support Care Cancer; 2018 Apr; 26(4):1273-1279. PubMed ID: 29090385
[TBL] [Abstract][Full Text] [Related]
7. Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study.
Araz M; Karaagac M; Korkmaz L; Koral L; Inci F; Beypinar I; Uysal M; Artac M
Cancer Chemother Pharmacol; 2019 Jun; 83(6):1091-1097. PubMed ID: 30963213
[TBL] [Abstract][Full Text] [Related]
8. Comparable safety and antiemetic efficacy of a brief (30-second bolus) intravenous granisetron infusion and a standard (15-minute) intravenous ondansetron infusion in breast cancer patients receiving moderately emetogenic chemotherapy.
Perez EA; Lembersky B; Kaywin P; Kalman L; Yocom K; Friedman C
Cancer J Sci Am; 1998; 4(1):52-8. PubMed ID: 9467047
[TBL] [Abstract][Full Text] [Related]
9. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): a multicentre, randomised, controlled phase 3 trial.
Nishimura J; Satoh T; Fukunaga M; Takemoto H; Nakata K; Ide Y; Fukuzaki T; Kudo T; Miyake Y; Yasui M; Morita S; Sakai D; Uemura M; Hata T; Takemasa I; Mizushima T; Ohno Y; Yamamoto H; Sekimoto M; Nezu R; Doki Y; Mori M;
Eur J Cancer; 2015 Jul; 51(10):1274-82. PubMed ID: 25922233
[TBL] [Abstract][Full Text] [Related]
10. The NK-1 receptor-antagonist aprepitant in high-dose chemotherapy (high-dose melphalan and high-dose T-ICE: paclitaxel, ifosfamide, carboplatin, etoposide): efficacy and safety of a triple antiemetic combination.
Jordan K; Jahn F; Jahn P; Behlendorf T; Stein A; Ruessel J; Kegel T; Schmoll HJ
Bone Marrow Transplant; 2011 Jun; 46(6):784-9. PubMed ID: 20838387
[TBL] [Abstract][Full Text] [Related]
11. Palonosetron versus granisetron in combination with aprepitant for the prevention of chemotherapy-induced nausea and vomiting in patients with gynecologic cancer.
Fujiwara S; Terai Y; Tsunetoh S; Sasaki H; Kanemura M; Ohmichi M
J Gynecol Oncol; 2015 Oct; 26(4):311-9. PubMed ID: 26197776
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of aprepitant for the prevention of chemotherapy-induced nausea and vomiting during the first cycle of moderately emetogenic chemotherapy in Korean patients with a broad range of tumor types.
Kim JE; Jang JS; Kim JW; Sung YL; Cho CH; Lee MA; Kim DJ; Ahn MJ; Lee KY; Sym SJ; Lim MC; Jung H; Cho EK; Min KW
Support Care Cancer; 2017 Mar; 25(3):801-809. PubMed ID: 27826874
[TBL] [Abstract][Full Text] [Related]
13. Efficacy, Safety And Feasibility Of Antiemetic Prophylaxis With Fosaprepitant, Granisetron And Dexamethasone In Pediatric Patients With Hemato-Oncological Malignancies.
Cabanillas Stanchi KM; Ebinger M; Hartmann U; Queudeville M; Feucht J; Ost M; Koch MS; Malaval C; Mezger M; Schober S; Weber S; Michaelis S; Lange V; Lang P; Handgretinger R; Döring M
Drug Des Devel Ther; 2019; 13():3439-3451. PubMed ID: 31686784
[TBL] [Abstract][Full Text] [Related]
14. Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy, and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized, single-blinded crossover study.
Kimura H; Yamamoto N; Shirai T; Nishida H; Hayashi K; Tanzawa Y; Takeuchi A; Igarashi K; Inatani H; Shimozaki S; Kato T; Aoki Y; Higuchi T; Tsuchiya H
Cancer Med; 2015 Mar; 4(3):333-41. PubMed ID: 25533447
[TBL] [Abstract][Full Text] [Related]
15. Safety and efficacy of a triple antiemetic combination with the NK-1 antagonist aprepitant in highly and moderately emetogenic multiple-day chemotherapy.
Jordan K; Kinitz I; Voigt W; Behlendorf T; Wolf HH; Schmoll HJ
Eur J Cancer; 2009 May; 45(7):1184-1187. PubMed ID: 19135359
[TBL] [Abstract][Full Text] [Related]
16. Aprepitant plus palonosetron and dexamethasone for prevention of chemotherapy-induced nausea and vomiting in patients receiving multiple-day cisplatin chemotherapy.
Gao HF; Liang Y; Zhou NN; Zhang DS; Wu HY
Intern Med J; 2013 Jan; 43(1):73-6. PubMed ID: 22141732
[TBL] [Abstract][Full Text] [Related]
17. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of aprepitant for chemotherapy-induced nausea and vomiting in pediatric patients: a prospective, observational study.
Bodge M; Shillingburg A; Paul S; Biondo L
Pediatr Blood Cancer; 2014 Jun; 61(6):1111-3. PubMed ID: 24357337
[TBL] [Abstract][Full Text] [Related]
19. A phase 2 study of fosaprepitant combined with high-dose dexamethasone for Japanese cancer patients receiving highly emetogenic chemotherapy.
Kumagai H; Kusaba H; Yamanaka T; Nio K; Inadomi K; Takayoshi K; Ito M; Tamura S; Makiyama A; Makiyama C; Hirano G; Shibata Y; Shirakawa T; Mitsugi K; Ariyama H; Esaki T; Akashi K; Baba E
Medicine (Baltimore); 2018 Jun; 97(25):e11042. PubMed ID: 29923992
[TBL] [Abstract][Full Text] [Related]
20. Comparison between Antiemetic Effects of Palonosetron and Granisetron on Chemotherapy-Induced Nausea and Vomiting in Japanese Patients Treated with R-CHOP.
Uchida M; Mori Y; Nakamura T; Kato K; Kamezaki K; Takenaka K; Shiratsuchi M; Kadoyama K; Miyamoto T; Akashi K
Biol Pharm Bull; 2017; 40(9):1499-1505. PubMed ID: 28867732
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]